All articles
Rare disease
How medical communicators can close the gap between rare disease breakthroughs and the patients who need them
Federal and state policy
State Statute Oncology Drug Coverage Report
Coverage and payment
Commercial Payers’ Use of Oncology Compendia
Federal and state policy
Biosimilar Substitution State Statute Report
Drug pricing and affordability
Effectuation and Standard Default Refund Amount: The dilemma of competitive drug classes
Drug pricing and affordability
340B purchases surge past $100 billion
Drug pricing and affordability
State pricing controls at an inflection point: Maximum Fair Price and the shifting Prescription Drug Affordability Board landscape
RWE and patient-centered outcomes
2026 dyslipidemia guideline signals a new standard for cardiovascular risk management
Drug pricing and affordability
Negotiated Part B drug effectuation proposals: Four Standard Default Refund Amount approaches and key trade-offs
Federal and state policy
2027 National Average Monthly Bid Amount signals continued market pressures in Part D